Therapeutic Potential and Critical Analysis of Trastuzumab and Bevacizumab in Combination with Different Chemotherapeutic Agents against Metastatic Breast/Colorectal Cancer Affecting Various Endpoints

Highlights • The combination of trastuzumab with different chemotherapeutic agents increases the median time to disease progression by 28–130% wherein paclitaxel shows the maximum because of synergism. • Bevacizumab with combinatorial compound IFL does exceptionally well to increase progression free...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2016-08, Vol.104, p.124-130
Main Authors: Wahid, Mohd, Mandal, Raju K, Dar, Sajad A, Jawed, Arshad, Lohani, Mohtashim, Areeshi, Mohammed Y, Akhter, Naseem, Haque, Shafiul
Format: Article
Language:English
Subjects:
Anthracycline
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Bevacizumab - administration & dosage
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Cyclophosphamide
Fluorouracil
Hematology, Oncology and Palliative Medicine
Humans
Irinotecan
Leucovorin
Metastatic breast cancer
Metastatic colorectal cancer
Paclitaxel
Trastuzumab
Trastuzumab - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The combination of trastuzumab with different chemotherapeutic agents increases the median time to disease progression by 28–130% wherein paclitaxel shows the maximum because of synergism. • Bevacizumab with combinatorial compound IFL does exceptionally well to increase progression free survival by 71%. • This study recommends the use of multiple chemotherapeutic agents with monoclonal antibodies that may have synergistic or additive effect on the overall treatment.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2016.06.009